Filtered By:
Cancer: Breast Cancer
Drug: Estradiol

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 59 results found since Jan 2013.

Selective Non-nuclear Estrogen Receptor Activation Decreases Stroke Severity and Promotes Functional Recovery in Female Mice.
Abstract Estrogens provide neuroprotection in animal models of stroke, but uterotrophic effects and cancer risk limit translation. Classical estrogen receptors (ER) serve as transcription factors, whereas non-nuclear ER govern numerous cell processes and exert beneficial cardiometabolic effects without uterine or breast cancer growth in mice. Here we determined how non-nuclear ER stimulation with a pathway-preferential estrogen (PaPE-1) impacts stroke outcome in mice.Ovariectomized female mice received vehicle, estradiol (E2), or PaPE-1 before and following transient middle cerebral artery occlusion (tMCAo). MRI a...
Source: Endocrinology - September 25, 2018 Category: Endocrinology Authors: Selvaraj UM, Zuurbier K, Whoolery C, Plautz EJ, Chambliss KL, Kong X, Zhang S, Kim SH, Katzenellenbogen BS, Katzenellenbogen JA, Mineo C, Shaul PW, Stowe AM Tags: Endocrinology Source Type: research

HRT optimization, using transdermal estradiol plus micronized progesterone, a safer HRT.
Abstract ABSTRACT Hormone replacement therapy (HRT) remains the gold standard for treatment of climacteric symptoms in menopausal women; it is relatively safe in healthy subjects for at least 5 years, provided it had been initiated before the age of 60 years and/or within 10 years from menopause. Estrogen probably adds some cardioprotection, that can, however, be obscured by progestogens, especially medroxyprogesterone acetate (MPA). Oral HRT is associated with an increased risk of venous thromboembolism (VTE), gallbladder disease and possibly stroke. The increased occurrence of all these events can be prevented b...
Source: Climacteric - July 19, 2013 Category: Geriatrics Authors: L'hermite M Tags: Climacteric Source Type: research

Managing menopause.
Authors: Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, Menopause and Osteoporosis Working Group, Fortier M, Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Graves L, Guthrie B, Khan A, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W Abstract OBJECTIVE: To provide updated guidelines for health care providers on the management of menopause in asymptomatic healthy women as well as in women presenting with vasomotor or urogenital symptoms and on considerations related to cardiovascular disease, breast cancer, urogynaecology, and sexuality. OUTCOMES: Lifestyle...
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - December 2, 2014 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research

Sex Differences in Sex Hormone Profiles and Prediction of Consciousness Recovery After Severe Traumatic Brain Injury
Conclusion: These findings indicate that TBI differentially affects the levels of sex-steroid hormones in men and women patients. Plasma levels of testosterone could be a good candidate blood marker to predict recovery from unconsciousness after sTBI for male patients. Introduction Traumatic brain injury (TBI) is a major cause of death and disability worldwide and is increasing in incidence (1). Patients with acute severe TBI (sTBI) often develop severe disorders of consciousness, i.e., coma, minimally conscious state or vegetative state. Although many patients may regain consciousness during the 1-month post-TBI p...
Source: Frontiers in Endocrinology - April 25, 2019 Category: Endocrinology Source Type: research

In assessing risk of hormone therapy for menopause, dose — not form — matters
FINDINGSWhen it comes to assessing the risk of estrogen therapy for menopause, how the therapy is delivered — taking a pill versus wearing a patch on one’s skin — doesn’t affect risk or benefit, researchers at UCLA and elsewhere have found. But with the commonly used conjugated equine estrogen, plus progestogen, the dosage does. Higher doses, especially over time, are associated with greater risk of problems, including heart disease and some types of cancer, especially among obese women.BACKGROUNDThe Women ’s Health Initiative established the potential of estrogen therapy to increase or decrease the risk of strok...
Source: UCLA Newsroom: Health Sciences - July 27, 2017 Category: Universities & Medical Training Source Type: news

Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s?
Scientists have discovered that certain antibodies may help slow the progression of Alzheimer’s disease. Dr. Patricia Salinas of University College London, UK, and her team focused on a protein called Dkk1, present in raised levels in the brains of people with Alzheimer’s disease. Using brain samples from mice, the team looked at the progressive disintegration of synapses in the hippocampus when exposed to a protein called amyloid-beta, thought to be central to the development of Alzheimer’s disease. “Synaptic loss mediated by amyloid-beta in early stages of the disease might contribute to cognitive...
Source: Psych Central - June 1, 2013 Category: Psychiatry Authors: Jane Collingwood Tags: Aging Alzheimer's Disorders General Seniors Abnormal Deposits Alzheimer S Disease Antibodies Brain Area Brain Damage Cognitive Decline Cognitive Impairments Disintegration Dr Patricia Dr Simon Hippocampus Journal Of Neurosc Source Type: news

Long‐term safety of unopposed estrogen used by women surviving myocardial infarction: 14‐year follow‐up of the ESPRIT randomised controlled trial
ConclusionsThese results suggest that unopposed estrogen may be used safely by women with an intact uterus surviving a first myocardial infarction.
Source: BJOG: An International Journal of Obstetrics and Gynaecology - February 18, 2014 Category: OBGYN Authors: N Cherry, R McNamee, A Heagerty, H Kitchener, P Hannaford Tags: Original Article Source Type: research

Long-term safety of unopposed estrogen used by women surviving myocardial infarction: 14-year follow-up of the ESPRIT randomised controlled trial.
CONCLUSIONS: These results suggest that unopposed estrogen may be used safely by women with an intact uterus surviving a first myocardial infarction. PMID: 24533510 [PubMed - as supplied by publisher]
Source: BJOG : An International Journal of Obstetrics and Gynaecology - February 18, 2014 Category: OBGYN Authors: Cherry N, McNamee R, Heagerty A, Kitchener H, Hannaford P Tags: BJOG Source Type: research

What have we learned about GPER function in physiology and disease from knockout mice?
Publication date: Available online 16 July 2015 Source:The Journal of Steroid Biochemistry and Molecular Biology Author(s): Eric R. Prossnitz, Helen J. Hathaway Estrogens, predominantly 17β-estradiol, exert diverse effects throughout the body in both normal and patho-physiology, during development and in reproductive, metabolic, endocrine, cardiovascular, nervous, musculoskeletal and immune systems. Estrogen and its receptors also play important roles in carcinogenesis and therapy, particularly for breast cancer. In addition to the classical nuclear estrogen receptors (ERα and ERβ) that traditionally mediate predomi...
Source: The Journal of Steroid Biochemistry and Molecular Biology - July 17, 2015 Category: Biochemistry Source Type: research

Bioidentical hormones for women with vasomotor symptoms.
CONCLUSIONS: There was low to moderate quality evidence that BHT in various forms and doses is more effective than placebo for treating moderate to severe menopausal hot flushes. There was low to moderate quality evidence of higher rates of adverse effects such as headache, vaginal bleeding, breast tenderness and skin reactions in the BHT group. There was some evidence to suggest that higher doses of BHT are associated with greater effectiveness but also with higher risk of adverse effects. Although all the included studies used unopposed estrogen, it is recommended best practice to use progestogen therapy in women with a ...
Source: Cochrane Database of Systematic Reviews - July 31, 2016 Category: Journals (General) Authors: Gaudard AM, Silva de Souza S, Puga ME, Marjoribanks J, da Silva EM, Torloni MR Tags: Cochrane Database Syst Rev Source Type: research

Endocrine Disruptors and Health Effects in Africa: A Call for Action
Conclusion: To address the many challenges posed by EDCs, we argue that Africans should take the lead in prioritization and evaluation of environmental hazards, including EDCs. We recommend the institution of education and training programs for chemical users, adoption of the precautionary principle, establishment of biomonitoring programs, and funding of community-based epidemiology and wildlife research programs led and funded by African institutes and private companies. https://doi.org/10.1289/EHP1774 Received: 16 February 2017 Revised: 22 May 2017 Accepted: 24 May 2017 Published: 22 August 2017 Address correspond...
Source: EHP Research - August 23, 2017 Category: Environmental Health Authors: Daniil Lyalko Tags: Commentary Source Type: research

Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study
Conclusions: The summary index of risks versus benefits was similar for oral CEE versus oral or transdermal E2-containing regimens. CEE + P containing less than 0.625 mg/d of CEE (vs 0.625 mg/d) for less than 5 years appeared safer.
Source: Menopause - September 23, 2017 Category: OBGYN Tags: Original Articles Source Type: research

Individual Benefits and Risks of Intravaginal Estrogen and Systemic Testosterone in the Management of Women in the Menopause, With a Discussion of Any Associated Risks for Cancer Development
Cancer J. 2022 May-Jun 01;28(3):196-203. doi: 10.1097/PPO.0000000000000598.ABSTRACTSeveral formulations of intravaginal oestrogen are available for the treatment of genitourinary syndrome of menopause (GSM). These are safe and effective treatments for the symptoms of GSM. Licensed doses of intravaginal oestrogen do not elevate systemic estradiol levels above the normal postmenopausal range with long term use and there is no evidence of an increased risk of coronary heart disease, stroke, thromboembolism, colorectal cancer, endometrial cancer, breast cancer or breast cancer recurrence with their use. This should reassure bo...
Source: Cancer Journal - May 20, 2022 Category: Cancer & Oncology Authors: Abbie J Laing Louise Newson James A Simon Source Type: research